NewGenIvf Group Limited Class A Ordinary Shares (NIVF)

FairStock Score: 59/100 — STEADY

Key Financials

Strengths

• High return on equity of 79.4% demonstrating efficient capital deployment
• Conservative balance sheet with debt-to-equity of just 0.19, providing financial flexibility

Concerns

• Weak Piotroski F-Score of 3/9 suggests deteriorating financial quality across multiple dimensions
• Altman Z-Score of 0.2 places it in the financial distress zone—elevated bankruptcy risk

AI Analysis

NewGenIvf Group Limited Class A Ordinary Shares is a micro-cap healthcare company valued at $1 million. Revenue stands at $5 million. From a quality standpoint, NewGenIvf shows weak Piotroski F-Score of 3/9 signaling deteriorating fundamentals and distressed Altman Z-Score of 0.2 warrants caution. On valuation, the stock is deeply undervalued on a P/E basis at 0.1x, with offers a 99% margin of safety vs Graham Number of $301. Growth dynamics show revenue growing at 11.8% and profit growth of -6984.9%. Our composite FairStock Score of 59/100 reflects mixed fundamentals overall. This combination of reasonable valuation, solid returns, and conservative leverage makes it worth a closer look for value-oriented portfolios.

Bull Case

The market underappreciates NewGenIvf's consistent 79% ROE at just 0x earnings—a re-rating toward sector peers could unlock 30-50% upside. Operational leverage in the business model means incremental revenue growth could disproportionately boost bottom-line profitability.

Bear Case

Macro headwinds or sector-specific disruption could pressure margins, particularly if competitive intensity increases in the healthcare space. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer